脂肪组织NLRP3炎性体：肥胖和2型糖尿病的治疗靶点

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-08-13 DOI:10.1016/j.drudis.2025.104456

Ngozi Francisca Nnolum-Orji, Pradeep Kumar, Lindokuhle Malibongwe Ngema, Yahya Essop Choonara

{"title":"脂肪组织NLRP3炎性体：肥胖和2型糖尿病的治疗靶点","authors":"Ngozi Francisca Nnolum-Orji, Pradeep Kumar, Lindokuhle Malibongwe Ngema, Yahya Essop Choonara","doi":"10.1016/j.drudis.2025.104456","DOIUrl":null,"url":null,"abstract":"<div><div>Adipose tissue has been identified as a crucial player in the release of proinflammatory mediators, which can result in a chronic inflammatory state, predisposing individuals to obesity, insulin resistance (IR), and type 2 diabetes mellitus (T2DM). A major approach in tackling these diseases involves targeting molecular sensors that can respond to nutritional cues and metabolic status that trigger the early phases of inflammatory cascades. Among these sensors is the nucleotide oligomerization domain (NOD)-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Therapeutic strategies targeting the adipose tissue NLRP3 inflammasome show potential for the management of obesity and T2DM. In this review, we provide insights into this potential, the current therapeutic strategies, and recent clinical advances.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 9","pages":"Article 104456"},"PeriodicalIF":7.5000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus\",\"authors\":\"Ngozi Francisca Nnolum-Orji, Pradeep Kumar, Lindokuhle Malibongwe Ngema, Yahya Essop Choonara\",\"doi\":\"10.1016/j.drudis.2025.104456\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Adipose tissue has been identified as a crucial player in the release of proinflammatory mediators, which can result in a chronic inflammatory state, predisposing individuals to obesity, insulin resistance (IR), and type 2 diabetes mellitus (T2DM). A major approach in tackling these diseases involves targeting molecular sensors that can respond to nutritional cues and metabolic status that trigger the early phases of inflammatory cascades. Among these sensors is the nucleotide oligomerization domain (NOD)-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Therapeutic strategies targeting the adipose tissue NLRP3 inflammasome show potential for the management of obesity and T2DM. In this review, we provide insights into this potential, the current therapeutic strategies, and recent clinical advances.</div></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"30 9\",\"pages\":\"Article 104456\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644625001692\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001692","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

脂肪组织在促炎介质的释放中起着至关重要的作用，促炎介质可导致慢性炎症状态，使个体易患肥胖、胰岛素抵抗（IR）和2型糖尿病（T2DM）。治疗这些疾病的一个主要方法是靶向分子传感器，这些传感器可以对营养线索和代谢状态做出反应，从而触发炎症级联反应的早期阶段。这些传感器包括核苷酸寡聚化结构域(NOD)-、富含亮氨酸的重复序列-和含pyrin结构域蛋白3 （NLRP3）炎症小体。针对脂肪组织NLRP3炎性体的治疗策略显示出治疗肥胖和2型糖尿病的潜力。在这篇综述中，我们提供了对这种潜力的见解，目前的治疗策略，以及最近的临床进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus

查看原文本刊更多论文

Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus

Adipose tissue has been identified as a crucial player in the release of proinflammatory mediators, which can result in a chronic inflammatory state, predisposing individuals to obesity, insulin resistance (IR), and type 2 diabetes mellitus (T2DM). A major approach in tackling these diseases involves targeting molecular sensors that can respond to nutritional cues and metabolic status that trigger the early phases of inflammatory cascades. Among these sensors is the nucleotide oligomerization domain (NOD)-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Therapeutic strategies targeting the adipose tissue NLRP3 inflammasome show potential for the management of obesity and T2DM. In this review, we provide insights into this potential, the current therapeutic strategies, and recent clinical advances.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.